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Abstract
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 24% of the global adult population. NAFLD is
a major risk factor for the development of cirrhosis and hepatocellular carcinoma, as well as being strongly
associated with type 2 diabetes and cardiovascular disease. It has been proposed that up to 88% of obese adults have
NAFLD, and with global obesity rates increasing, this disease is set to become even more prevalent. Despite intense
research in this field, the molecular processes underlying the pathology of NAFLD remain poorly understood.
Hepatic intracellular lipid accumulation may lead to dysregulated tricarboxylic acid (TCA) cycle activity and
associated alterations in metabolite levels. The TCA cycle metabolites alpha-ketoglutarate, succinate and
fumarate are allosteric regulators of the alpha-ketoglutarate-dependent dioxygenase family of enzymes. The
enzymes within this family have multiple targets, including DNA and chromatin, and thus may be capable of
modulating gene transcription in response to intracellular lipid accumulation through alteration of the epigenome. In
this review, we discuss what is currently understood in the field and suggest areas for future research which
may lead to the development of novel preventative or therapeutic interventions for NAFLD.
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Background
Globally, non-alcoholic fatty liver disease (NAFLD) is the
most common form of chronic liver disease [1], and com-
prises a spectrum of pathologies, from benign hepatic
steatosis to inflammatory non-alcoholic steatohepatitis
(NASH), liver cirrhosis, and hepatocellular carcinoma
(HCC) [2]. Benign hepatic steatosis is the most common
form of NAFLD and is characterised by a hepatic fat con-
tent of greater than 5% of total liver weight [3]. Approxi-
mately 37% of adult patients with benign steatosis will
develop NASH, which is strongly associated with hepatic
inflammation, insulin resistance (IR), and type 2 diabetes
(T2D) [4]. Despite much research aimed at developing
therapeutics to target the disease, currently, the only way
to reverse the development of benign steatosis or NASH
is through lifestyle modifications associated with weight
loss, including diet and exercise [5], or gastric banding [6],
for example, in a 5-year human study gastric banding was
shown to be effective in reversing hepatic steatosis,
NASH, and IR [6]. However this remains an invasive sur-
gical procedure, the risks of which are exacerbated in
overweight individuals [7]; indeed a systematic review of
the outcomes found that a subset of patients experienced
new or worsening features of NAFLD, including fibrosis,
demonstrating that this surgery is not suitable in all cases
[8]. A major hurdle in the development of therapeutics for
NAFLD is that the cause is multi-factorial [9]. Early stud-
ies advanced a two-hit model, in which benign steatosis,
characterised by the accumulation of intracellular triglyc-
erides, represents the first ‘hit’. The second hit involves
the additional presence of oxidative stress, the production
of inflammatory cytokines and mitochondrial dysfunction
[10]. This has now been further developed into a ‘mul-
tiple-hit’ model, which considers that numerous other
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factors may drive pathology, including diet and genetic
predisposition [11].
Obesity, type 2 diabetes, and NAFLD
The relationship between NAFLD, IR, and T2D is com-
plex, and although NAFLD and its progression are
strongly associated with the metabolic syndrome, it also
occurs in the absence of overt IR and T2D. Indeed,
epidemiological studies suggest that the presence of
NAFLD may be predictive of the development of IR and
T2D [3], but the precise molecular bases of these associ-
ations are not fully understood.
Hepatic steatosis is a consequence of an imbalance be-
tween hepatic lipid uptake, de novo lipogenesis, and lipid
clearance. In obesity, the excess accumulation of lipids
in visceral adipose tissue results in an increased release
of free fatty acids (FFAs) into the circulation, with FFAs
derived from adipose lipolysis being the principal source
of lipids supplied to the liver [12]. In the steady state,
stimulation of hepatic insulin receptors activates the
PKB/AKT pathway, inducing phosphorylation and nu-
clear exclusion of the fork-head box protein (FOXO1)
transcription factor [13]. In the presence of excess FFAs,
insulin receptor activation is blunted, leading to a dis-
ruption of the insulin signalling pathway [14]. This dis-
ruption prevents the phosphorylation of FOXO1,
allowing it to translocate to the nucleus, where it stimu-
lates the expression of genes associated with gluconeo-
genesis and de novo lipogenesis [15]. This can stimulate
hepatic intracellular lipid accumulation and the develop-
ment of large lipid droplets within the cytoplasm [16].
Overnutrition, accompanied by hyperinsulinemia and
hyperglycemia, drives steatosis by promoting de novo
lipogenesis in the liver which contributes substantially to
the accumulation of multiple lipid species [17]. Studies
in rodents have shown that obesity is associated with an
increase in the expression of lipogenic transcription fac-
tors, including carbohydrate response element binding
protein (ChREBP) and sterol regulatory element binding
protein-1c (SREBP-1c). This leads to a downstream in-
crease in the expression of lipogenic genes, increased
flux through acetyl-CoA carboxylase, and increased hep-
atic malonyl-CoA. These changes result in increased
hepatic de novo lipogenesis, suppressed hepatic fatty
acid oxidation, and the development of steatosis [18].
Further, the increase in hepatic diacylglycerol, which
binds to and activates protein kinase C [19], can in turn
inhibit the hepatic insulin signalling cascade [20]. FFAs
also repress the expression of glucose transporter 4
(GLUT4), and studies in immortalised primary human
hepatocytes suggest that the subsequent increase in
intracellular glucose levels can stimulate glucokinase ac-
tivity, providing more substrates for glycolysis through
conversion of glucose to glucose-6-phosphate [21] and
further contributing to de novo lipogenesis [22]. In-
creased rates of glycolysis may also provide pyruvate,
which can be used as a substrate for the TCA cycle.
Mitochondria and the TCA cycle in NAFLD
Studies in humans and mice indicate that alterations in
mitochondrial TCA cycle activity may play a central role
in the pathogenesis of NAFLD [23, 24]. The TCA cycle
occurs predominantly in the mitochondrial matrix and is
a central pathway for the metabolism of amino acids,
fatty acids, and carbohydrates, in order to generate cellu-
lar energy [25]. The cycle utilises the substrate acetyl co-
enzyme A (acetyl-CoA), which is generated by glycolysis
via pyruvate, through the action of pyruvate dehydrogen-
ase (PDH) [26] and through amino acid degradation and
β-oxidation. Acetyl-CoA is oxidised through a series of
steps, producing NADH and FADH2, which transfer
electrons to the electron transport chain to fuel the pro-
duction of ATP. Pyruvate can also be carboxylated by
pyruvate carboxylase (PC) to form oxaloacetate (OAA),
which then undergoes a condensation reaction with
acetyl-CoA to form citrate (Fig. 1). Additionally, the
TCA cycle can be fuelled by the deamination of glutam-
ate by glutamate dehydrogenase, to produce α-ketoglutarate
(αKG) [27]. Increased influx of substrates into the
TCA cycle can increase cycle flux, as well as the
abundance of the intermediates αKG, succinate, and
fumarate [28].
Whilst the TCA cycle is typically a feature of the mito-
chondria, specific TCA cycle reactions can also occur in
the cytoplasm [29] and the nucleus [30] (Fig. 1). For ex-
ample, αKG can be generated in the cytoplasm by glu-
tamate dehydrogenase, before being transported into the
mitochondria. The malate/aspartate shuttle exports as-
partate to the cytoplasm, where it is converted to oxalo-
acetate, and then to malate, whilst also oxidising NADH
to NAD+. Malate and NAD+ are then transported back
into the mitochondria, and αKG is simultaneously
exported to the cytoplasm. Data from studies in PC12
cells suggest that alterations in the balance of NADH
and NAD+ may play a role in the development of fatty
liver, through increased oxidative stress [31] and disrup-
tion of β-oxidation, leading to increased lipid accumula-
tion [32]. There are mitochondrial and cytoplasmic
forms of the TCA cycle enzymes isocitrate dehydrogen-
ase (IDH) and malate dehydrogenase (MDH). Fumarate
hydratase, which only exists in one form, is most com-
monly located in the mitochondria but can be found in
the cytoplasm and can translocate to the nucleus upon
DNA damage [33]. Furthermore, several mitochondrial
TCA cycle enzymes, including PDH, PC, and isocitrate
dehydrogenase 3 (IDH3), can translocate to the nucleus,
where they ultimately generate αKG [30], although to
date this has only been demonstrated during a time-
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limited phase of zygotic genome activation. The gener-
ation and presence of TCA cycle metabolites in multiple
cellular compartments increase the chance of them be-
ing able to interact with a number of enzymes, and this
will be discussed later in this review.
Whilst the standard model of the TCA cycle describes
a unidirectional process, the landscape is more complex
than this. Instead of OAA condensing with acetyl-CoA
to form citrate, it can instead be converted to malate,
then fumarate, and back to malate and OAA, in a
process termed ‘backflux’ [34]. Truncation of the TCA
cycle is also possible in certain disease states, including
hypoglycaemia and in various cancers, in which specific
steps are no longer functional and are bypassed. During
hypoglycaemia, for example, glutamate can become the
primary source of carbon, allowing OAA to be generated
from αKG instead of citrate [35]. Loss of FH function, as
found in some cancers, results in the accumulation of
fumarate and a corresponding decrease in NADH gener-
ation [36]. However, despite these metabolic alterations
fumarate hydratase-deficient cells (UOK262 cell line) are
viable, and resist hypoxia, perhaps through stabilisation
of hypoxia-inducible factors [36], which will be discussed
later in this review. The plasticity of the TCA cycle
serves to illustrate that it can undergo complex adapta-
tions in pathological states and promote cell survival.
Hepatic lipid accumulation is associated with mito-
chondrial dysfunction and oxidative stress, through
disruption of mitochondrial energy metabolism path-
ways [17, 37–39]. Studies in human and animal models
show that the transport of excess FFAs into the mito-
chondria leads to compensatory adaptations, which in-
crease the rates of β-oxidation, TCA cycle flux, and
oxidative phosphorylation [23, 40, 41]. These alterations
are associated with increased reactive oxygen species
(ROS) generation, lipid peroxidation, and apoptosis [42],
which may contribute to the inflammatory phenotype
observed in patients with NASH. Humans with NASH
demonstrate increased expression of mitochondrial un-
coupling protein 2 (UCP2), which may occur in response
to increased ROS production [43]. UCP2 uncouples the
electron transport chain, by increasing proton leakage
and lowering redox stress through decreased reactive
ROS production [44]. Whilst this may initially be
beneficial, it may eventually become detrimental in
chronic conditions such as NAFLD, leading to mito-
chondrial dysfunction, with loss of electron transport
chain efficiency, decreased production of adenosine
triphosphate (ATP), and increased ROS generation
[45, 46].
Evidence from studies in humans and in mouse
models suggests that TCA cycle activity is increased in
NAFLD, with increased cycle flux and replenishment
(anaplerosis) of αKG via glutamate. Although the evi-
dence for this is compelling, the technical difficulties of
obtaining human tissue samples mean that many of the
Fig. 1 The TCA cycle occurs predominantly in the mitochondrial matrix, although some reactions can occur beyond the mitochondria, including
in the cytoplasm and nucleus. Solid arrows represent the reaction direction (enzymes omitted for simplicity), whilst dashed arrows represent the
transport of metabolites into the cytoplasm
Sinton et al. Clinical Epigenetics          (2019) 11:104 Page 3 of 12
changes in hepatic TCA cycle flux and anaplerosis which
have been described in human studies have been in-
ferred from peripheral blood, and thus the results may
be confounded by the release of metabolites from other
tissues [23]. Although there are limited data from
humans with NASH suggesting that αKG is decreased in
diseased hepatic tissue [47], the tissue samples were first
embedded in paraffin with downstream metabolomic
analysis which may confound some of the results [48],
so that further studies would be useful to confirm these
findings. Nuclear magnetic resonance (NMR) studies
also indicate increased hepatic TCA cycle flux and ana-
plerosis in human NAFLD [23] and studies in the livers
of mice fed a high-fat diet demonstrate increased TCA
cycle flux associated with hepatic steatosis [49]. The use
of whole tissue to examine the effects of NAFLD on
metabolic function can make it difficult to determine
which cells within a tissue are exhibiting altered TCA
cycle activity. However, a recently developed in vitro
model, which uses embryonic stem cell (ESC)-derived
hepatocytes to model NAFLD, supports the assertion
that intracellular lipid accumulation associates with dys-
regulation of the TCA cycle and altered abundance of
intermediates [50].
The αKG-dependent dioxygenases
In addition to its central role in energy metabolism,
components of the TCA cycle can influence the catalytic
activity of the αKG-dependent dioxygenase family of en-
zymes [51]. The αKG-dependent dioxygenases are
Fe(II)/O2-dependent enzymes, which catalyse the hy-
droxylation of a number of substrates, including DNA,
histones, and proteins. The enzyme family includes the
prolyl-4-hydroxylases (PHD), Jumonji domain-containing
histone demethylases (JHDMs), and ten-eleven transloca-
tion (TET) dioxygenases [52]. All of the enzymes within
this family have two binding domains in their β-sheet
core, which are highly specific for αKG, and binding of
αKG acts as a positive regulator of dioxygenase activity
[53, 54]. Conversely, these two domains can be competi-
tively bound by succinate and fumarate, which inhibit
dioxygenase activity [55]
The functions of these enzyme members are numerous
but include epigenetic regulation, through DNA methy-
lation, histone methylation, and acetylation, as well as
oxygen sensing through the PHDs [56–58]. It is tempt-
ing to speculate, therefore, that the αKG-dependent
dioxygenases could form a nexus, integrating environ-
mental signals and disseminating them to downstream
targets by altering gene transcription to allow cells to
maintain homeostasis. Thus, dysfunctional mitochon-
drial (TCA cycle) metabolism could impact on epigen-
etic modifications of DNA and chromatin through
alterations in JHDM, PHD, and TET enzyme activity,
and findings from human breast and colon cancer cell
lines open up the possibility that this may also play a
role in NAFLD [59–61].
Prolyl-4-hydroxylases, HIF-1α, and NAFLD
PHDs catalyse the most prevalent post-translational
modification (PTM) in humans, hydroxylating proline
residues to form (2S,4R)-4-hydroxyproline [62]. Whilst
PHDs have many substrates, including Argonaut 2 [63],
collagen [64], and elastin [65], one of the most well char-
acterised are the hypoxia-inducible factor (HIF) tran-
scription factors, which are targeted by PHD2 [66]. HIF-
1 is comprised of two constitutively expressed sub-units:
HIF-1α and HIF-1β [62]. Under normal oxygen condi-
tions (normoxia), PHDs hydroxylate two proline residues
(Pro402 and Pro564) within the oxygen-dependent deg-
radation domain of HIF-1α [62]. The hydroxylation of
these proline residues recruits ubiquitin E3 ligase and
leads to the polyubiquitination of HIF-1α, marking it
for degradation by the proteasome [67]. Under hyp-
oxic conditions, low oxygen concentrations diminish
the ability of PHDs to hydroxylate these proline resi-
dues, and thus HIF-1α stabilises, allowing it to trans-
locate to the nucleus where it can dimerise with HIF-
1β, bind to hypoxia response elements, and facilitate
gene transcription [68] (Fig. 2).
Despite their name, it is not only oxygen that regulates
the HIFs. Since PHDs are also regulated by succinate, fu-
marate, and αKG, HIFs are able to coordinate gene net-
works in response to metabolic rewiring [69, 70].
Indeed, in human breast cancer cell lines, hypoxia is as-
sociated with lipid homeostasis, through coordination of
genes regulating lipid droplet formation, de novo lipo-
genesis, and fatty acid uptake [71]. Whilst there is a lack
of data to directly link TCA cycle dysfunction in NAFLD
with PHD inhibition and HIF stabilisation, there are lim-
ited data from rat models demonstrating altered HIF-1α
mRNA and protein levels in steatotic whole liver [72]. A
caveat to this study is that it was performed in whole tis-
sue, and perivenous regions of the liver express higher
levels of HIF mRNA [73] so that disease-associated alter-
ations in hepatic structure and/or variation in the region
of the liver sampled could influence the results. How-
ever, in support of this link, studies suggest that there is
a relationship between lipid accumulation and HIF-1α
stabilisation [74]. Both HIF-1α mRNA and protein levels
increase in the adipose tissue of obese subjects, and
there is strong evidence that obesity provokes a hypoxia-
like response in adipose tissue [75, 76]. Tracer studies in
mice, using a 13C-glucose stable isotope, demonstrated
an increase in the abundance of αKG, succinate, and fu-
marate in the adipose tissue of obese animals [24]. Fur-
thermore, this study found increased levels of succinate
in the liver of obese mice, suggesting that obesity is
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associated with alterations in metabolites that have the
potential to impact on the activity of PHDs [24].
There are conflicting reports as to whether HIF-1α
plays a protective or harmful role in NAFLD [72, 77].
Using a rat model of liver steatosis, Carabelli et al. de-
scribe increased expression of HIF-1α mRNA in the liver
and suggest that this is responsible for an observed in-
crease in mitochondrial biogenesis [72]. They also
speculate that this may form a protective mechanism,
whereby hepatocytes are able to increase rates of β-oxi-
dation to process excess intracellular lipids [72]. In con-
trast, Mesarwi et al. observed that HIF-1α mediates the
development of hepatic fibrosis in a mouse model of
NAFLD, suggesting a pathogenic role [77]. The discrep-
ancies between these studies could be explained by the
use of different animal models. It may also be a result of
NAFLD comprising a spectrum of pathology, whereby
some molecular mechanisms may be protective during
the early stage of disease, but eventually become chronic
and harmful. However, there is a lack of data to suggest
whether HIF-1α is important for the development of
NAFLD in humans and for any impact of TCA cycle
dysfunction on PHD catalytic activity. Nevertheless,
PHD2 contains a histone-binding domain [78], can
translocate to the nucleus, and is found within the chro-
matin fraction [62], suggesting that it may directly im-
pact on gene transcription.
JHDMs, histone modifications, and NAFLD
Histone proteins form cores around which DNA can
condense, allowing it to be packaged efficiently into nu-
cleosomes, to form chromatin [79]. These nucleosomes
can be highly compacted, preventing the transcription of
DNA to mRNA [80]. Histones are also subject to many
PTMs, including acetylation, methylation, phosphoryl-
ation, sumoylation, and ubiquitylation [81]. Depending
upon the deposition site of PTMs, they can result in
chromatin condensation and transcriptional silencing
[82] or associate with relaxation of chromatin and active
gene transcription [82].
The JHDMs are a large family of αKG-dependent
dioxygenases that can catalyse the removal of mono-,
di-, and trimethylation marks from specific lysine (K)
residues of histone 3 (H3) or histone 4 (H4) [83, 84].
Each JHDM targets a specific histone lysine residue,
which impacts on chromatin structure in multiple ways,
depending on the resulting methylation pattern. Broadly,
methylation of H3K9 and H3K27 is associated with
chromatin compaction and transcriptional silencing [85].
In contrast, H3K4 and H3K36 methylation are typically
associated with chromatin relaxation and transcriptional
activity [85]. However, enrichments of H3K9 di- and tri-
methylation have been observed in transcriptionally ac-
tive euchromatic regions of genes [86], demonstrating
that the impact of histone methylation on gene tran-
scription is complex and nuanced.
The activity of the JHDMs can be influenced by TCA
cycle metabolites, for example, the experimental silen-
cing of succinate dehydrogenase in a human HCC cell
line leads to the accumulation of succinate, with result-
ant inhibition of the JHDMs, altered histone methylation
patterns, and changes in transcriptional activity [87].
Although there is no direct evidence to link TCA
cycle dysfunction with alterations in JHDM activity in
NAFLD, in a mouse model, hepatic steatosis occurred
in association with altered JHDM expression and al-
tered H3K4 and H3K9 trimethylation at the peroxi-
some proliferator-activated receptor alpha (PPARα)
Fig. 2 TCA cycle metabolites in the cytoplasm can interact with prolyl-4-hydroxylases, to either promote or repress activity. Repression prevents
ubiquitination of HIF-1α, promoting protein stabilisation, followed by nuclear accumulation and transcription of target genes
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gene and in a number of other genes important in
lipid catabolism [88].
DNA methylation and NAFLD
DNA methylation is a highly conserved epigenetic modi-
fication involving the addition of a methyl group at the
C5 position of cytosine, predominantly in cytosine-phos-
phate-guanine (CpG) dinucleotides, to form 5-methylcy-
tosine (5mC) [89]. The reactions are catalysed by the
DNA methyltransferases (DNMTs). Approximately 10%
of CpG sites are located in clusters termed CpG islands
(CGIs) and are most commonly found in the promoters
of genes with important developmental functions [90].
In general, these CGIs are unmethylated, but where
methylation does occur, it can be associated with tran-
scriptional repression and heterochromatic regions, as
5mC is, in general, thought to prevent transcription fac-
tor binding [91]. During development, it is estimated
that fewer than 30% of CpGs are methylated, in contrast
to 85% in terminally differentiated cells, illustrating the
tight control that is exerted to retain cell homeostasis
and phenotype in differentiated cells [92]. The TET en-
zymes are a subset of the αKG-dependent dioxygenase
family, comprised of TET1, TET2, and TET3. These en-
zymes catalyse the iterative oxidation and demethylation
of 5mC to 5-hydroxymethylcytosine (5hmC), 5-formyl-
cytosine (5fC), and 5-carboxylcytosine (5caC), before
base excision repair (BER) is triggered, resulting in un-
modified cytosine [56] (Fig. 3). To achieve this, the
double-stranded β-helix at the N-terminus of the TET
enzymes brings together Fe(II), αKG, and 5mC to allow
oxidation of the methyl group to 5hmC, 5fC, and 5caC
[56]. The contiguous cysteine-rich domain then wraps
around the double-stranded β-helix to stabilise the inter-
action between the TET enzyme and the DNA, facilitat-
ing the oxidation reaction [56]. Whilst initially thought
to be transient, 5hmC is now accepted as a stable cyto-
sine modification [93], and 5hmC enrichment within
gene bodies and enhancers broadly correlates with tran-
scriptional activation [94, 95]. In contrast, 5hmC enrich-
ment within gene transcriptional start sites (TSS) is
associated with transcriptional repression and the
maintenance of CpG hypomethylation [96]. As with
other enzymes in the αKG-dependent dioxygenase
family, TET catalytic activity is modulated by the
TCA cycle metabolites αKG, succinate, and fumarate
[55]. This may be important in some human cancers,
for example, loss of function mutations in fumarate
hydratase and succinate dehydrogenase in human cer-
vical cancer and glioblastoma cell lines result in the
accumulation of fumarate and succinate, respectively,
with consequent inhibition of TET enzyme activity
and altered 5hmC levels [55].
The development of hepatic steatosis is associated
with changes in hepatic DNA methylation in a methio-
nine-deficient diet (MDD) model of NAFLD in mice
[97]. In this study, it is not known where in the genome
these changes occur, making it difficult to infer any im-
pact on transcriptional regulation. Furthermore, there
are concerns as to how well the MDD model recapitu-
lates NAFLD, as shown by suppressed expression of very
low-density lipoprotein carboxylesterase mRNA [98]. In
contrast, Pirola et al. observed that humans with NASH
have increased DNMT1 mRNA and a concurrent in-
crease in DNA methylation of the mitochondrial NADH
dehydrogenase 6 gene in the whole liver [99]. The
Fig. 3 TET1 oxidation of 5mC through to unmodified cytosine. After the deposition of 5-methylcytosine by the DNMT enzymes it can be oxidised
by the TETs to 5-hydroxymethylcytosine, 5-formylcytosine, and then 5-carboxylcytosine, before base excision repair resulting in unmodified
cytosine. These iterative oxidation steps can be inhibited by the TCA cycle metabolites succinate and fumarate
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importance of mitochondrial DNA methylation is de-
bated [100, 101], and it is therefore currently uncertain
what impact it may have on the pathogenesis of NAFLD.
Evidence of altered nuclear DNA methylation in the
liver in NAFLD is supported by a number of studies in
humans. Differential methylation has been reported in
liver biopsy specimens from patients with NAFLD [102,
103], with some studies showing an inverse correlation
between gene expression and DNA methylation [104].
Specific differentially methylated regions have been iden-
tified which may associate with NAFLD progression
[105]. Notably, some of the changes in DNA methylation
may be reversible with weight loss, for example follow-
ing bariatric surgery [104, 105]. There is also evidence
from bariatric surgery patients suggesting that there is a
correlation between altered DNA methylation and
changes in hepatic insulin signalling [106]. A recent
study focused on understanding the link between
NAFLD-associated liver fibrosis and cirrhosis and DNA
methylation performed bisulfite sequencing in liver biop-
sies from female patients undergoing bariatric surgery,
who had no other liver-related pathologies [107]. The
study identified differential CpG island methylation at a
number of different genes and gene ontology analysis
showed enrichment for a number of pathways related to
NAFLD, including reactive oxygen species production
and T2D signalling [107]. Whilst compelling, the find-
ings in each of these studies are correlative and do not
describe any mechanism(s) by which altered DNA
methylation might occur. In addition, the studies used
bisulfite treatment to analyse DNA methylation, making
it impossible to determine if they were observing
changes in 5mC or its oxidised counterpart 5hmC.
There is evidence to suggest that 5hmC levels are al-
tered in NAFLD. Patient studies describe a positive asso-
ciation between global hepatic 5hmC levels and the
expression of peroxisome proliferator-activated receptor
γ (PPARγ) coactivator 1α (PPARGC1A), a gene at which
DNA methylation has previously been associated with
NAFLD and IR [99, 108]. The lack of any change in glo-
bal 5hmC could reflect the use of whole tissue, which
may dilute the 5hmC signal through analysis of multiple
cell types or alternatively may indicate that alterations in
5hmC in response to NAFLD occur only at specific
genes. Indeed, using an in vitro model of NAFLD, we
have recently shown that changes in 5hmC levels occur
specifically at induced genes associated with lipid syn-
thesis and transport [50]. Further, we found altered ex-
pression of several genes encoding TCA cycle enzymes,
including succinate dehydrogenase, isocitrate dehydro-
genase, and an accumulation of the TCA cycle metabol-
ite oxalosuccinate, suggesting altered cycle activity. The
importance of the TET enzymes and 5hmC in liver dis-
ease is further supported by studies showing that
aberrant TET1 activity in hepatocellular carcinoma is
associated with loss of 5hmC and a gain of 5mC, with
subsequent transcriptional repression, suggesting that
the TETs may normally prevent DNMT binding in these
regions in the healthy liver [109].
TET1 and histone methylation
In human ES cells, TET1 may orchestrate the activity of
components of the epigenetic machinery by targeting
genes for binding by the polycomb recessive complex
(PRC). Though they do not appear to physically interact,
TET1 appears to recruit PRC2 to particular genes [110],
possibly by maintaining a hypomethylated state, as DNA
methylation prevents binding by PRC2 [111]. Upon
binding to hypomethylated DNA, PRC2 can di- or tri-
methylate H3K27, an epigenetic mark associated with
transcriptional repression [112, 113]. This may be rele-
vant to the pathogenesis of NAFLD, since genome-wide
association studies have shown enrichment of PRC2
pathways in humans with NASH [114]. In support of
this, data from rat liver and human liver cell lines have
demonstrated that downregulation of core components
of PRC2 is associated with the de-repression of inflam-
matory genes and intracellular lipid accumulation [115].
Thus, whilst TET1 may not directly control the DNA-
binding activity of PRC2 in the pathogenesis of NAFLD,
these data suggest that it may facilitate it.
Post-translational regulation of TET activity
In addition to regulation by TCA cycle metabolites,
Fe(II), and oxygen, the TET enzymes are also regulated
by PTMs, including phosphorylation and O-GlcNAcyla-
tion. The O-GlcNAcylation PTM is deposited by O-
linked N-acetylglucosamine transferase (OGT), which at-
taches an N-acetyl glucosamine to serine and threonine
residues within target proteins [116]. Disruption of the
OGT binding site in TET1 reduces genomic 5hmC
levels, with a concurrent reduction in gene expression
[117]. The post-translational addition of O-GlcNAcyla-
tion to proteins is promoted by the hexosamine biosyn-
thetic pathway (HBP), which synthesises N-GlcNAc
from glucose, linking elevated intracellular glucose to in-
creased O-GlcNAcylation [118]. This generates a posi-
tive feedback loop, whereby the HBP diverts glucose
away from glycolysis, and lowers αKG levels. This, in
turn, promotes stabilisation of HIF-1α via PHD inhib-
ition and promotes increased transcription of the glu-
cose transporter 1 (GLUT1) gene [119], allowing more
glucose to enter the cell. The reduction of αKG in re-
sponse to elevated O-GlcNAcylation could indicate that,
whilst TCA cycle intermediates play a direct role in TET
enzyme function, they may also play an indirect role
through the modulation of PTMs. Indeed, the impact of
increased HBP activity, subsequent stabilisation of HIF-
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1α, and ensuing increase in intracellular glucose may be
more important for directing the activity of the TETs.
This is relevant, since NAFLD is strongly associated with
T2D, hepatic IR, and poor glucose clearance [120]. In
addition, studies in mouse models and human tissue
show that OGT also promotes the transition from hep-
atic steatosis to HCC [121]. Whilst this effect is thought
to be mediated by palmitic acid production and endo-
plasmic reticulum stress, other avenues have not yet
been explored. In mouse ES cells, OGT can form a com-
plex with TET1 or TET2 in the nucleus, anchoring them
to histones and DNA [122], and since genomic hypome-
thylation is a hallmark of HCCs [123], it is possible that
this complex may be involved in its development. This
adds to the wealth of evidence suggesting that the TET
enzymes and 5hmC may play a role at all stages of
NAFLD pathogenesis, and its progression to HCC.
Future perspectives
The study of epigenetic dysregulation in disease is fraught
with difficulties and limitations, not least whether changes
in epigenetic marks are a cause or consequence of the dis-
ease process itself [124]. In addition to this, many studies
in the NAFLD field have reported changes in genome
methylation, but have arrived at their conclusions based
on bisulfite sequencing data [99, 104]. Since bisulfite se-
quencing cannot distinguish between 5mC and 5hmC
[125], it is impossible to determine precisely which
changes are occurring during the pathogenesis of
NAFLD in much of the current literature. Further to
these difficulties are the inherent limitations of the
current models of NAFLD, which make it difficult to
study the interplay between the TCA cycle and epi-
genetic modifications. It is technically difficult, and
highly invasive, to obtain liver samples from humans,
and controls are often not taken from healthy donors
but individuals being investigated for pathologies
other than NAFLD [104]. The use of whole tissue
samples from humans or animals makes it challenging
to attribute phenotypes to a particular cell type. This
could, typically, be overcome through the use of
fluorescence activated cell sorting, but recent studies
have shown that this alters the redox status of cells
[126], potentially confounding analyses of changes in
the TCA cycle. The use of HCC cell lines is also
challenging, since malignant transformation often re-
sults in metabolic derangement [127]. The develop-
ment and refinement of 2-D and 3-D in vitro models
of ‘NAFLD in a dish’ using a single cell type may be
useful for future mechanistic and therapeutic studies, in-
cluding the careful dissection of the interplay between
TCA cycle dysfunction and epigenetic regulation of gene
expression in the pathogenesis of the disease [50, 128]
Conclusions
As the obesity pandemic continues, the number of
people living with NAFLD will continue to grow, in-
creasing the economic burden on healthcare systems
globally [129], making it critical that new strategies
for the treatment of the disease are developed. Stud-
ies of the interplay between TCA cycle dysfunction
and regulation of the αKG-dependent dioxygenases in
new models may provide a more comprehensive pic-
ture of the processes underlying NAFLD and lead to
the development of predictive tests or new diagnos-
tics, alongside novel therapeutics, which are able to
reverse the disease.
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